Browsing by Author Scott, Russell

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2009The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study.Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Tse, D; D'Emden, Michael C.; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; O'Brien, Richard; Scott, Russell; Taskinen, M.; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study., Diabetes Care, vol.32,(3),2009,pp 493-498
2014HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 DiabetesGebski, Val; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Waldman, Boris; Davis, Timothy M. E.; Ng, Martin K C; Scott, Russell; Taskinen, M.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreHDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes, Diabetes Care, vol.37, 8, 2014,pp 2351-2358
2011Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trialDonoghoe, Mark; Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Colman, P. G.; Davis, T. M. E.; Manning, Patrick; O'Brien, Richard; Scott, Russell; Taskinen, M.; Watts, Gerald F.; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial, Cardiovascular Diabetology, vol.10, 1, 2011,pp 102-1-102-8
2010A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trialsByth Wilson, Karen; Keech, Anthony (Tony); O'Connell, Rachel; Pardy, Christopher; Simes, Robert John; Voysey, Merryn; Best, James; Ehnholm, Christian; Glasziou, Paul; Scott, Russell; Sullivan, David; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials, P L o S One, vol.5, 1,pp e8580-1-e8580-10
2015PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialSullivan, David; Bridges, Ian; Burgess, Leslie; Cariou, B; Civeira, Fernando; Dufour, Robert; Gaudet, Daniel; Gouni-Berthold, Ioanna; Hovingh, G Kees; Langslet, Gisle; Olsson, Anders; Raal, Frederick J; Scott, Rob; Scott, Russell; Somaratne, Ransi; Stein, Evan; Turner, Traci; Wasserman, Scott M.; NH&MRC Clinical Trials CentrePCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.385, 9965, 2015,pp 331-340
2015Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyBarter, Philip; Buizen, L; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Ong, Kwok; Rye, Kerry-Anne; Sullivan, David; Scott, Russell; Taskinen, M; Xu, Aimin; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Heart Research Institute; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials CentreRelationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study, Diabetologia, vol.59, 8, 2015,pp 2035-2044
2015The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes studyBarter, Philip; Hung, Wei Ting; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Ong, Kwok; Rye, Kerry-Anne; Sullivan, David; Scott, Russell; Taskinen, M.; Xu, Aimin; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Heart Research Institute; Other or Unknown; NH&MRC Clinical Trials CentreThe relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study, Diabetologia, vol.58, 3, 2015,pp 464-473
2015Serum 25-Hydroxy Vitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 DiabetesJenkins, Alicia; Keech, Anthony (Tony); Sullivan, David; Veillard, Anne-Sophie; Blankenberg, Stefan; Burton, Anthony; Herrmann, Markus; Laakso, Markku; McCorquodale, Thomas; Scott, Russell; Straub, Isabella R; Topliss, Duncan J.; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreSerum 25-Hydroxy Vitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes, Diabetes Care, vol.38, 3, 2015,pp 521-528
2004Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetesBarter, Philip; Forder, Peta; Keech, Anthony (Tony); Simes, Robert John; Best, James; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Scott, Russell; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSignificant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes, Journal of the American College of Cardiology, vol.43, 5,pp A462-A462
2009Using the EQ-D index score as a predictor of outcomes in patients with type 2 diabetes.Clarke, Philip; Hayes, Alison; Keech, Anthony (Tony); Simes, Robert John; Glasziou, Paul; Scott, Russell; School of Public Health: Public Health; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreUsing the EQ-D index score as a predictor of outcomes in patients with type 2 diabetes., Medical Care, vol.47,(1),2009,pp 61-68